Italian diagnostics firm DiaSorin has agreed to buy U.S. rival Luminex Corp for $1.8 billion in a move that could boost its molecular business and offset a potential drop in demand for COVID-19 tests as the pandemic is brought under control.
The pandemic has fuelled rapid growth at Diasorin’s molecular division, which in 2020 accounted for 29% of sales. But as the rollout of COVID-19 vaccines progresses, some analysts have raised concern about a possible drop in demand for COVID-19 molecular tests once the emergency is over.
The deal, which grows DiaSorin’s footprint in the key U.S. market, follows a similar acquisition by diagnostics rival Roche, which bought GenMark Diagnostics in a $1.8 billion deal to fill a testing portfolio gap.
Luminex will be merged with a newly formed U.S. subsidiary of DiaSorin. The combined group would have had 2020 revenues of around $1.5 billion.
Read more at Reuters
By Giancarlo Navach
Image Source
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.